GB2068969A - Gene expression - Google Patents
Gene expression Download PDFInfo
- Publication number
- GB2068969A GB2068969A GB8100462A GB8100462A GB2068969A GB 2068969 A GB2068969 A GB 2068969A GB 8100462 A GB8100462 A GB 8100462A GB 8100462 A GB8100462 A GB 8100462A GB 2068969 A GB2068969 A GB 2068969A
- Authority
- GB
- United Kingdom
- Prior art keywords
- process according
- gene
- plasmid
- vehicle
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 36
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 claims abstract description 12
- 230000002103 transcriptional effect Effects 0.000 claims abstract description 6
- 230000000977 initiatory effect Effects 0.000 claims abstract description 5
- 239000013612 plasmid Substances 0.000 claims description 34
- 241001465754 Metazoa Species 0.000 claims description 5
- 235000021120 animal protein Nutrition 0.000 claims description 5
- 108020004999 messenger RNA Proteins 0.000 claims description 5
- 241000287828 Gallus gallus Species 0.000 claims description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 108010064851 Plant Proteins Proteins 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 235000021118 plant-derived protein Nutrition 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 22
- 102000004169 proteins and genes Human genes 0.000 abstract description 12
- 108020004414 DNA Proteins 0.000 description 25
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 21
- 108010058846 Ovalbumin Proteins 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 15
- 229940092253 ovalbumin Drugs 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 9
- 239000007983 Tris buffer Substances 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- 229960000723 ampicillin Drugs 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 229960005542 ethidium bromide Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 101100285000 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) his-3 gene Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101500013104 Pelophylax ridibundus Secretoneurin Proteins 0.000 description 1
- 241000364057 Peoria Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 108010087005 glusulase Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000006151 minimal media Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/77—Ovalbumin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Abstract
A process for the expression of a gene, foreign to a host organism, coding for a protein, in a suitable vehicle, which comprises taking said gene and fusing it in the correct orientation relative to a transcriptional initiation region present in the vehicle, and inserting the vehicle into a eukaryotic host. For example, the gene for chicken ovalbumin can be expressed in the yeast Saccharomyces cerevisiae.
Description
SPECIFICATION
Gene expression
Many benefits in the medical field are envisaged as a result of the application of recombinant DNA technology. This technology requires the insertion, into host organisms, of genes able to direct the biosynthesis of required proteins. In most cases, a protein of interest will normally be synthesised in animal cells and will not be found naturally in yeast or other lower eukaryotes. Although it has been possible to clone a number of different animal genes containing the information necessary to code for proteins, there are few reports of the expression of these proteins in bacteria and other unicellular organisms. Some which have been expressed in E. coli are the human polypeptide hormone somatostatin (Itakura eft at Science 198 (1977) 1056--1063), rat proinsulin, and human insulin chains.
The chicken ovalbumin gene has been successfully expressed in E. coli Hub101, by fusing the gene near transcriptional and translational initiation regions. See Proceedings of National
Academy of Sciences 6 (1978) 5936-5940. We have now found that the chicken ovalbumin structural gene can be fused to, for example, a
S. cerevisiae transcriptional control region.
According to the present invention, a process for the expression of a gene in a vehicle, the gene coding for an animal or plant protein, comprises fusing the gene in the correct orientation relative to a transcriptional initiation region present in the vehicle, and inserting the vehicle into a eukaryotic host.
By way of example, when a plasmid containing the chicken ovalbumin structural hybrid gene is introduced into S. cerevisiae, a protein identified as ovalbumin by immunoreactivity and polyacrylamide gel electrophoresis can be synthesised. The chicken ovalbumin made in yeast is full-length (43,000 MW) and constitutes approximately 1,500 molecules per cell. We believe that this is the first animal protein expressed in yeast.
Examples of other proteins which can be produced using a gene inserted by the process of the present invention are human serum albumin, human interferons, human antibodies, human insulin, blood clotting factors, brain peptides, enzymes, viral antigens, and proteins from plants.
The gene may be derived from a plant or animal virus. Broadly, the invention relates to the expression of gene coding for proteins which are foreign to the host organism.
Preferabiy, the gene codes for an animal protein. The gene is suitably isolated from a vertebrate which is preferably warm-blooded, more preferably a bird and most preferably a chicken. The invention is particularly suited to the expression of genes coding for chicken ovalbumin.
A structural gene coding for a eukaryotic protein can generally be prepared using its purified messenger RNA (mRNA) as starting material. A complementary DNA (cDNA) copy of the mRNA is enzymatically synthesised and then enzymatically made double-stranded. This gene is then joined to a suitable cloning vehicle, usually by the poly dA; poly dT tailing procedure (Jackson eft at Proc.
Nat. Acad. Sci. (69 (1972) 2904-2909), although this is not always necessary. The vehicle containing the structural gene is then amplified in bacteria. This procedure has been used to prepare the pOV 230 plasmid, as well as plasmids containing globin genes and insulin genes.
Examples of other vehicles which can be used in the invention are any that can replicate within yeast, such as a plasmid, e.g. YEp2, YEp4, YRp7,
YEp20 or, preferably, YEp6. Vectors which can replicate in other lower eukaryotic hosts can be used.
Examples of hosts for the vehicle are
S. cerevisiae and derivatives thereof. The host is preferably a unicellular organism such as a fungus.
It is recognised that these latter hosts would have to be approved, at least in the USA, by the NIH
Guidelines.
The plasmids (YEp6, pOV 230 and pUC 1014) described herein have been deposited in E. coli hosts in the permanent collection of the Northern
Regional Research Laboratory, US Department of
Agriculture, Peoria, Illinois, USA. Their accession numbers in this repository are HB101-NRRL B 11371;HBl0l (pOV230)-NRRLB-11354; HB101 (YEp 6)-NRRL B-12093; and HB101 (pUC 101 4)-NRRL B-12094. These NRRL deposits were made on 26th July 1 978 (B 11354),9th August 1978 (B-11371) and 31 st January 1980 (B-12093 and B-12094).
pUC 1014 has also been deposited in
S. cerevisiae SHY 3 strain which is an NIH approved HV 2 host. The accession numbers of these yeast deposits are: S cerevisiae SHY 3 strain-NRRL Y-1 2095 and CBS (Holland) 8026;
SHY 3 (pUC 1014)-NRRLY-12096 and CBS 8025. These two NRRL deposits were made on 31st January 1980.
The YEp6 plasmid (Struhl etna!., Proc. Nat.
Acad. Sci. 76(1979)1035-1039) contains an
E. coli replication origin and ampicillin resistance marker derived from pBR322 so that it can be maintained in E. coli. In addition it contains a yeast plasmid replication origin and yeast His3 gene so that it can be maintained in his- yeast auxothrophs. The YEp6 plasmid also has a unique
Sal I restriction endonuclease site which can be used for cloning foreign DNA.
Construction of the YEp6-ovalbumin fused plasmid, pUC 1014, proceeds as shown in the accompanying drawing. Although the abbreviations used here and throughout are conventional and well known to those skilled in the art, they are redefined here to facilitate a clear understanding of the invention:
Restriction endonucleases: SAL I (in the
Example).
Tc' -- tetracycline resistance gene.
ampr - ampicillin resistance gene.
Yeast his 3 gene - gene coding for an enzyme required for the biosynthesis of histidine in yeast.
T4 DNA ligase -- enzyme coded for by bacteriophage T4.
YEp - yeast episomal plasmid.
pUC - official designation for a plasmid owned by The Upjohn Company.
pOV - plasmid ovalbumin.
Ovalbumin gene -- chicken ovalbumin structural gene.
The YEp6 plasmid is cut with Sal I and the resulting linear molecule is treated, advantageously with alkaline phosphatase, to remove the 5' phosphate groups on the ends of the molecule.
The pOV 230 plasmid contains nearly all of the ovalbumin mRNA sequence, including all of the information required to code for the amino acid sequence of chicken ovalbumin [McReynolds,
L. A., Catterall, J. F. and O'Malley, B. W. (1977) Gene 2: 217--231]. This plasmid is cut with Sal I, ligated with the alkaline phosphatase-treated,
Sal I cut YEp6 and transformed into E. coli.
Transformants are selected on ampicillin plates and their plasmid DNA's analyzed.
There are two possible orientations of the ovalbumin gene relative to the YEp6 plasmid, and these can be distinguished by Bam H1 digestion of the DNA and agarose gel electrophoresis.
Preparations of the plasmid DNA's are made by growth in E. coli and used to transform
S. cerevisiae. His+ transformations are selected on supplemented minimal media plates under conditions where the His parents can not grow.
The transformants are then grown in broth and lysed by passage through a French pressure cell.
The extracts are analyzed for ovalbumin immunoreactivity with an 1251 solid phase radioimmunoassay.
As determined by this immunoassay, only one of the two possible orientations of the ovalbumin gene relative to the YEp6 plasmid is capable of directing the synthesis of ovalbumin in yeast. The hybrid plasmid with this orientation, called pUC 1014, requires transcription of the ovalbumin gene in the counterclockwise direction of the plasmid illustrated in the drawing. The other orientation requires transcription in the clockwise direction. Thus, the ovalbumin gene is only expressed in yeast if it is fused into the YEp6 plasmid in the correct orientation relative to a yeast transcriptional initiation region.
Polyacrylamide gel electrophoresis of the chicken ovalbumin made in yeast indicates that it migrates with a mobility almost identical to that of ovalbumin synthesized in chicken oviduct. Some differences in mobility would be expected due to incomplete post-translational modifications of the ovalbumin made in yeast. Thus, the normal translational initiation site of the chicken gene is most probably used by the yeast translational machinery.
The following examples are illustrative of the process and products of the subject invention but are not to be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.
EXAMPLE 1
DNA Preparation
pOV 230 Plasmid DNA from NRRL B-11354 is isolated by the salt precipitation technique described by Guerry eft at [Guerry, P., LeBlanc,
D. J. and Falkow, S. (1973) J. Bact. 116: 1064-1066]. L-broth [Lennox, E.S. (1955) Virology 1: 190--206] containing 10 Mg/ml tetracycline is inoculated with an overnight broth culture of NRRL B-11354. Cultures are shaken vigorously at 370 C. until the optical density at 600 nm reaches 0.8; plasmid copy number is then amplified for 18 hours with chloramphenicol (250 g/ml). Cells are washed once in 50 mM
Tris HCl, pH 8.0, 20 mM EDTA, and resuspended in 33 ml of 25% sucrose in TE (10 mM Tris HCI, pH 8.0,0.1 mM EDTA) per liter of culture.
Following the addition of 1 mg/ml lysozyme, the suspension is incubated on ice for five minutes, followed by addition of 1/3 volume of 0.25 M
EDTA, pH 8.0 and another 5 minute incubation on ice. Cells are lysed by addition of 10% sodium dodecyl sulfate (SDS) in 37 mM Tris HCI, pH 8.0, 67 mM EDTA, to a final concentration of 1.3% followed by incubation at 370 C. for 30 minutes.
Chromosomal DNA is salted out by bringing the
NaCI concentration to 1 M; followed by cooling at 40 C. overnight. SDS and chromosomal DNA are removed by centrifuging at 17,000 x g for 30 minutes at 40 C. The resulting supernatant is ethanol precipitated, pelleted, and redissolved in
TE. This material is phenol extracted twice, ether extracted, ethanol precipitated, pelleted and resuspended in TE.
Plasmid DNA is further purified by cesium chloride-ethidium bromide density gradient centrifugation. Cesium chloride is dissolved in the
DNA solution at a ratio of 1:1 (wt. vol.), followed by addition of 550 Lg/ml ethidium bromide.
Gradients are centrifuged for approximately 40 hours at ca. 100,000 x g. Plasmid DNA is removed from the gradient by needle puncture, and the ethidium bromide extracted with H20saturated 1-butanol. DNA is then dialyzed in 10 mM Tris HCI, pH 8.0,0.1 mM EDTA, followed by a final ethanol precipitation. Purified plasmid
DNA is dissolved in 10 mM Tris HCI, pH 8.0, 0.1 mM EDTA.
If ampicillin is substituted for tetracycline in the method described above for preparing pOV 230
DNA, the method can also be used to prepare
YEp6 DNA and pUC 1014 DNA in E. coli. Other plasmid DNA's can be prepared by this method if an appropriate selection (i.e., another antibiotic) is used to maintain the plasmid in the culture. Also, it is within the skill of those in the art to vary the above conditions to prepare plasmid DNA.
EXAMPLE 2
Restriction Endonuclease Digestions
Sal I digestion of YEp6 DNA and pOV 230 DNA, prepared as described in Example 1, is done in a reaction mixture containing 6 mM Tris HCI, pH 8.0,6 mM MgCI2, 150 mM NaCI, 6 mM ,B- mercaptoethanol, 100 Mgm/ml autoclaved gelatin, 80 ygm/ml DNA and 80 units/ml Sal I restriction endonuclease. After incubation for 60 minutes at 370 C., the reaction mixture is phenol extracted, ether extracted and ethanol precipitated. It should be realized that the use of another vehicle might require the use of a different restriction endonuclease.
It is within the skill of those in the art to vary the concentrations of reagents, substrates and enzymes as well as reaction conditions to obtain the desired cleavages.
EXAMPLE 3
Alkaline Phosphatase Treatment
This procedure is carried out essentially as described by Ullrich et al. [Ullrich, A., Shine, J.,
Chirgwin, J., Pictet, R., Tischer, E., Rutter, W. J.
and Goodman, H. M. (1977) Science 196: 131 3-i 31 9] with some minor modifications.
Twelve Units/ml of bacterial alkaline phosphatase (BAPF, Worthington) in 20 mM Tris HCI, pH 8.0, are pre-incubated at 700 C. for 10 minutes. One hundred Mgm/ml of Sal I cut YEp6 DNA, prepared as described in Example 2, is then added and incubation at 700 C. continues for 1 5 minutes.
The reaction mixture is then phenol extracted three times, ether extracted, and ethanol precipitated. This procedure is optional in the preparation of pUC 1014. However, use of the procedure affords a higher ratio of pUC 1014 to parental YEp6 plasmid among ampicillin resistant transformants, thereby facilitating the recovery of pUC 1014.
EXAMPLE4 T4 DNA Ligase
In order to ligate the pOV 230 DNA to the alkaline phosphatase treated YEp6 DNA, prepared as described in Example 3, the reaction mixture contains 50 mM Tris HCI, pH 7.8, 10 mM MgCI2, 20 mM dithiothreitol, 1 mM ATP, 30 ygm/ml YEp6 DNA, 6 Mg/ml Sal I cut pOV 230 and 15 Units/ml of T4 DNA ligase. After incubation for 1 6 hours at 12.50 C., the reaction mixture is ethanol precipitated and the pellet dissolved in
TCM (10 mM Tris HCI, pH 8.0, 10 mM CaCI2, 10 mM MgCI2). It is within the skill of those in the art to vary the concentrations of reagents, substrates and enzymes, as well as reaction conditions, to obtain the desired ligations.
EXAMPLE 5
Transformation of E. coli
One hundred twenty ml. of L-broth (1% tryptone, 0.5% yeast extract, 0.5% NaCI) are inoculated with an 18 hour culture of Hub 101 NRRL B-11371 and grown to an optical density of 0.6 at 600 nm. Cells are washed in cold 10 mM
MgSO4 and resuspended for 15 minutes in 20 ml chilled 50 mM CaCI2. Bacteria are then concentrated to one-tenth of this volume in CaCI2 and mixed 2 :1 (v :v) with ligated DNA, prepared as described in Example 4. After chilling the cell-DNA mixture for 1 5 minutes, it is heat shocked at 420 C. for 2 minutes, then allowed to equilibrate at room temperature for ten minutes before addition of L-broth 2-1/3 times the volume of the cell-DNA suspension.Transformed cells are incubated in broth at 370 C. for one hour before inoculating selective media (L-agar plus 20 4g/ml ampicillin) with 200 ,aVper plate. Plates are incubated at 370C, for 48 hours to allow the growth of transformants. Although the transformation procedure is essential for the amplification of biochemically constructed recombinant DNA molecules, the choice of conditions for such a procedure can be changed by those skilled in the art to achieve the desired purpose.
EXAMPLE 6
Transformation of NRRL Y-12095 to NRRL Y12096
SHY 3 strain of Saccharomyces cerevisiae (uratrp-leu-his-ade-), NRRL Y-i 2095 is transformed as follows: Twenty ml of log phase culture grown in YEPD broth (1% yeast extract, 2% peptone, 2% glucose) to an OD600 of 2.0 (3 x 107 cells/ml) were pelleted and resuspended in 1/10 volume 0.9 M sorbitol, 50 mM KPO4 buffer, pH 7.5, 14 mM p-mercaptoethanol. Spheroplasts are formed by addition of 1% Glusulase (Endo
Laboratories) and incubation at 300 C. for 60 minutes.After washing three times in 1 M sorbitol, spheroplasts are resuspended in 1/100 original culture volume of 1 M sorbitol, 10 mM
Tris-HCI, pH 7.5, 10 mM CaCI2. pUC 1014 DNA is added to a final concentration of 20,ug/ml. After incubation at room temperature for 5 minutes, 10 volumes of 40% polyethylene glycol 4000, 10 mM tris-HCI, pH 7.5, 10 mM CaC12 are added, followed by 10 minutes incubation at room temperature.His+ transformations are selected by overlaying minimal agar [0.7% yeast nitrogen base (Difco), 2% glucose,2% agarose, supplemented with 20 yg/ml uracil, adenine and tryptophan and 30 Mg/ml leucine] with 0.2 ml cells suspended in 10 ml molten (450 C.) regeneration medium (minimal medium containing 1 M sorbital, 2% YEPD and 3% agarose). Plates are incubated at 280 C. for 5-6 days.
EXAMPLE 7
Yeast Cell Extract Preparation
Yeast cells grown in 100 ml minimal medium at 280 C. to early stationary phase are washed in
Dulbecco's phosphate buffered saline (Gibso) and resuspended in extraction buffer (1 mM Tris-HCI pH 7.4, 1 mM MgCl2, 5 mM NaCI) at a ratio of 1:1 (volume in ml: cell weight in gm). The slurry is put through a French pressure cell twice at 15,000 PSI to lyse the cells.
EXAMPLE 8
Solid Phase Radioimmunoassay
This is done by a slight modification of the method described by Broome and Gilbert [Proc.
Nat. Acad. Sci., 75: 2746-2749, 1978].
Polyvinyl chloride sheets (8 mils thick, made by
Dora May Co., obtained at Woolworth's) 8 cm in diameter, are floated for 2 minutes at room temperature on 10 ml. of .2 M NaHCO3 (pH 9.2) containing 600 ssgm of the IgG fraction from antiovalbumin goat serum. The polyvinyl is then turned over and the other side coated. The polyvinyl is then washed with a solution (wash buffer) containing phosphate-buffered saline, 0.5% normal rabbit serum and 0.1% bovine serum albumin. After washing, the sheets are placed in contact with protein to be tested for the presence of immunoreactive ovalbumin. If cell lysates are to be tested, it is most convenient to spot the lysate on an agarose gel matrix. Proteins within a polyacrylamide gel matrix can also be tested after they had been separated by electrophoresis.The
IgG-coated polyvinyl is placed in contact with either the agarose or polyacrylamide gel matrixes, and incubated in the refrigerator (approximately 40 C.) for several hours. The polyvinyl sheet is then placed in contact with [1251] labelled antiovalbumin IgG and incubated overnight in the refrigerator. After rinsing in wash buffer, the sheets are autoradiographed with Kodak XR-5 film and a duPont Cronex Hi- plus intensifying screen at 700 C.
EXAMPLE 9
Purification of Ovalbumin
The transformed yeast cells of Example 6 are grown in minimal medium (0.7% yeast nitrogen base, 2% glucose supplemented with 20 mg/ml uracil, adenine and tryptophan, and 30 ssg/ml leucine) to early stationary phase, and washed in
Dulbecco's phosphate buffered saline (Gibco). The cells, contained ovalbumin, are then resuspended in extraction buffer (1 mM Tris-HCI, pH 7.4, 1 mM MgCl2, 5 mM NaCI) at a ratio of 1:1 (volume in ml: cell weight in gm). The slurry is put through a
French pressure cell at 1 5,000 PSI to lyse the cells. Purification to obtain crystalline ovalbumin, for use in the baking industry or for research purposes, carl be carried out as described by
Shepherd etna!. in Methods in Carbohydrate
Research Vol. VII (1976) ed. Whistier, and
BeMiller, Academic Press, New York, pages 1 72-1 74. Crystalline ovalbumin is listed in the sales catalogues of various fine chemical suppliers.
The plasmic pUC 1014 and the yeast culture
SHY 3 (pUC 1014) CBS 8025 form further aspects of the present invention. A further process of the present invention is for preparing chicken ovalbumin, a process comprising culturing
S. cerevisiae SHY 3 (pUC 1014) CBS 8025 in an aqueous nutrient medium. The conditions will normally be controlled as necessary.
Claims (20)
1. A process for the expression of a gene coding for an animal or plant protein in a vehicle, which comprises fusing the gene in the correct orientation relative to a transcriptional initiation region present in the vehicle, and inserting the vehicle into a eukaryotic host.
2. A process according to claim 1 wherein the gene codes for a plant protein.
3. A process according to claim 1 wherein the gene is from a plant virus.
4. A process according to claim 1 wherein the gene codes for an animal protein.
5. A process according to claim 1 wherein the gene is from an animal virus.
6. A process according to claim 4 wherein the gene is isolated from a vertebrate.
7. A process according to claim 6 wherein the vertebrate is warm-blooded.
8. A process according to claim 7 wherein the warm-blooded vertebrate is a bird.
9. A process according to claim 8 wherein the bird is a chicken.
10. A process according to claim 9 wherein the gene is the chicken ovalbumin structural gene.
11. A process according to any preceding claim wherein the vehicle is a plasmid.
12. A process according to claim 11 wherein the plasmid is YEp 6.
13. A process according to any preceding claim wherein the host is foreign to the gene.
14. A process according to any preceding claim wherein the host is a unicellular organism.
1 5. A process according to claim 14 wherein the transcriptional initiation region naturally initiates mRNA synthesis in the unicellular organism.
1 6. A process according to claim 1 substantially as exemplified herein.
1 7. A process according to claim 14 or claim 1 5 wherein the unicellular organism is a fungus.
1 8. A process for preparing chicken ovalbumin, which comprises culturing S. cerevisiae SHY 3 (pUC 1014), CBS 8025, in an aqueous nutrient medium.
19. SHY 3 (pUC 1014) CBS 8025.
20. Plasmid pUC 1014.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11903780A | 1980-02-05 | 1980-02-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
GB2068969A true GB2068969A (en) | 1981-08-19 |
GB2068969B GB2068969B (en) | 1983-07-27 |
Family
ID=22382245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB8100462A Expired GB2068969B (en) | 1980-02-05 | 1981-01-08 | Gene expression |
Country Status (5)
Country | Link |
---|---|
JP (1) | JPS56109588A (en) |
DE (1) | DE3102036A1 (en) |
FR (1) | FR2476126B1 (en) |
GB (1) | GB2068969B (en) |
IT (1) | IT8119504A0 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0068646A1 (en) * | 1981-06-08 | 1983-01-05 | The Upjohn Company | Process for expressing the bovine growth hormone gene, and plasmid for use therein |
EP0073635A2 (en) * | 1981-08-25 | 1983-03-09 | Celltech Limited | Expression vectors |
EP0088632A2 (en) * | 1982-03-08 | 1983-09-14 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
WO1984001173A1 (en) * | 1982-09-15 | 1984-03-29 | Immuno Nuclear Corp | Production of mature proteins in transformed yeast |
US4472502A (en) * | 1982-08-16 | 1984-09-18 | The Regents Of The University Of California | Malolactic gene |
EP0183070A2 (en) * | 1984-10-30 | 1986-06-04 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4803164A (en) * | 1981-08-31 | 1989-02-07 | Genentech, Inc. | Preparation of hepatitis b surface antigen in yeast |
US5045463A (en) * | 1983-12-20 | 1991-09-03 | Cetus Corporation | DNA expression vector and use thereof |
US5096825A (en) * | 1983-01-12 | 1992-03-17 | Chiron Corporation | Gene for human epidermal growth factor and synthesis and expression thereof |
WO1994028126A2 (en) * | 1993-05-20 | 1994-12-08 | University Of Warwick | Phenylalanine-free protein and dna coding therefor |
GB2294464A (en) * | 1993-05-20 | 1996-05-01 | University Of Warwick | Phanylalanine-free protien and dna coding therefor |
US5854018A (en) * | 1981-02-25 | 1998-12-29 | Washington Research Foundation | Expression of polypeptides in yeast |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58192900A (en) * | 1982-05-04 | 1983-11-10 | Ajinomoto Co Inc | Complex plasmid |
JPH0616713B2 (en) * | 1982-06-10 | 1994-03-09 | 味の素株式会社 | Complex plasmid |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2458585A1 (en) * | 1979-06-07 | 1981-01-02 | Pasteur Institut | Genetically engineered proteins for nutrition - prepd. from ovalbumin |
-
1981
- 1981-01-08 GB GB8100462A patent/GB2068969B/en not_active Expired
- 1981-01-19 JP JP523481A patent/JPS56109588A/en active Pending
- 1981-01-22 DE DE19813102036 patent/DE3102036A1/en not_active Withdrawn
- 1981-02-04 IT IT8119504A patent/IT8119504A0/en unknown
- 1981-02-04 FR FR8102155A patent/FR2476126B1/en not_active Expired
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5856123A (en) * | 1981-02-25 | 1999-01-05 | Washington Research Foundation | Expression of polypeptides in yeast |
US5919651A (en) * | 1981-02-25 | 1999-07-06 | Washington Research Foundation | Expression of polypeptides in yeast |
US5854018A (en) * | 1981-02-25 | 1998-12-29 | Washington Research Foundation | Expression of polypeptides in yeast |
EP0068646A1 (en) * | 1981-06-08 | 1983-01-05 | The Upjohn Company | Process for expressing the bovine growth hormone gene, and plasmid for use therein |
EP0073635A3 (en) * | 1981-08-25 | 1984-05-16 | Alan John Kingsman | Expression vectors |
US4615974A (en) * | 1981-08-25 | 1986-10-07 | Celltech Limited | Yeast expression vectors |
EP0073635A2 (en) * | 1981-08-25 | 1983-03-09 | Celltech Limited | Expression vectors |
US4803164A (en) * | 1981-08-31 | 1989-02-07 | Genentech, Inc. | Preparation of hepatitis b surface antigen in yeast |
GB2116567A (en) * | 1982-03-08 | 1983-09-28 | Genentech Inc | Expression processing and secretion of heterologous protein by yeast |
FR2523152A1 (en) * | 1982-03-08 | 1983-09-16 | Genentech Inc | PROTEIN PRODUCT FOR EXPRESSION AND TREATMENT BY A MICROORGANISM AND METHOD FOR PRODUCING THE SAME |
EP0088632A3 (en) * | 1982-03-08 | 1984-06-20 | Genentech, Inc. | Expression processing and secretion of heterologous protein by yeast |
EP0088632A2 (en) * | 1982-03-08 | 1983-09-14 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
US4472502A (en) * | 1982-08-16 | 1984-09-18 | The Regents Of The University Of California | Malolactic gene |
WO1984001173A1 (en) * | 1982-09-15 | 1984-03-29 | Immuno Nuclear Corp | Production of mature proteins in transformed yeast |
US5096825A (en) * | 1983-01-12 | 1992-03-17 | Chiron Corporation | Gene for human epidermal growth factor and synthesis and expression thereof |
US5045463A (en) * | 1983-12-20 | 1991-09-03 | Cetus Corporation | DNA expression vector and use thereof |
EP0183070A3 (en) * | 1984-10-30 | 1987-09-30 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
EP0183070A2 (en) * | 1984-10-30 | 1986-06-04 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
WO1994028126A2 (en) * | 1993-05-20 | 1994-12-08 | University Of Warwick | Phenylalanine-free protein and dna coding therefor |
WO1994028126A3 (en) * | 1993-05-20 | 1995-01-26 | Univ Warwick | Phenylalanine-free protein and dna coding therefor |
GB2294464A (en) * | 1993-05-20 | 1996-05-01 | University Of Warwick | Phanylalanine-free protien and dna coding therefor |
GB2294464B (en) * | 1993-05-20 | 1998-03-11 | Univ Warwick | Phenylalanine-free protein and DNA coding therefor |
US6495344B1 (en) | 1993-05-20 | 2002-12-17 | Pharming Holding N. V. | Phenylalanine-free protein and DNA coding therefor |
Also Published As
Publication number | Publication date |
---|---|
FR2476126B1 (en) | 1985-07-05 |
DE3102036A1 (en) | 1981-12-03 |
JPS56109588A (en) | 1981-08-31 |
GB2068969B (en) | 1983-07-27 |
IT8119504A0 (en) | 1981-02-04 |
FR2476126A1 (en) | 1981-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4443539A (en) | Process for preparing bovine growth hormone | |
KR890003083B1 (en) | Method for preparation of tetracycline resistance gene having microorganism | |
US4440859A (en) | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms | |
JP2552808B2 (en) | Method for producing polypeptide | |
GB2068969A (en) | Gene expression | |
US4430428A (en) | Composition of matter and process | |
US4382028A (en) | Separation of plasma proteins from cell culture systems | |
CA1340173C (en) | Production and purification of a protein fused to a binding protein | |
US4652525A (en) | Recombinant bacterial plasmids containing the coding sequences of insulin genes | |
JPH0665305B2 (en) | Method for stabilizing host cell containing recombinant DNA | |
WO1984004535A1 (en) | Heat regulated production of selected and fused proteins in yeast | |
Yeung et al. | The purification of the Escherichia coli UvrABC incision system | |
GB2033905A (en) | Bacterial preparation of proteins | |
US5082772A (en) | Process for preparing deacetylcephalosporin c | |
US4649119A (en) | Cloning systems for corynebacterium | |
JPS5998692A (en) | Introduction of external gene in green algae by utilizing t-dna of agrobacterium | |
Pugsley et al. | Increased production of the outer membrane receptors for colicins B, D and M by Escherichia coli under iron starvation | |
Vasantha et al. | Isolation of a developmental gene of Bacillus subtilis and its expression in Escherichia coli. | |
JPS6156093A (en) | Production of human white corpuscle interferon alpha-2 | |
EP0163573B1 (en) | Site-specific proteolysis by renin | |
EP0190119A1 (en) | Chimeric plasmids that replicate in bacteria and yeast and microorganisms transformed therewith | |
CA2078365C (en) | Pichia pastoris linear plasmids and dna fragments thereof | |
US5049501A (en) | Production method for PvuI restriction endonuclease | |
EP0506262B1 (en) | Production of L-fucose dehydrogenase | |
RU1660388C (en) | Recombinant plasmid dna pvgib encoding bovine gamma-interferon, method of its preparing and yeast strain saccharomyces cerevisiae - a producer of bovine gamma-interferon |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PCNP | Patent ceased through non-payment of renewal fee |